Dogwood's neuropathic pain drug Halneuron shows positive phase 2b results

Dogwood Therapeutics, Inc., a biopharmaceutical company in which CK Life Sciences Int'l. (Holdings) Inc. holds an approximate 83% indirect shareholding, announced positive interim results from its Halneuron Phase 2b study for chemotherapy-induced neuropathic pain (CINP) on December 22, 2025. An independent statistical review of 97 patients showed Halneuron-treated patients demonstrating pain improvement over placebo over a four-week period.

This preliminary evidence is significant given that patients in the interim analysis had an average CINP duration of 5 years and 67% were also on stable doses of other chronic pain medications. The study's low dropout rate of approximately 4.4% further supports Halneuron's safety profile. Dogwood expects top-line results for the study, which is projected to have 80% to 85% statistical power, by Q3 2026.

However, shareholders and potential investors are cautioned that Halneuron is still in Phase 2b, and data is subject to regulatory review, meaning there is no guarantee of the final outcome.